Oct 21, 2024 · At IDWeek 2024, Moderna presented interim results from an ongoing Phase I/II, randomised, observer-blind, placebo-controlled, dose-ranging trial (NCT05992935) for mRNA-1403, a prophylactic vaccine candidate under investigation for norovirus (NoV) infections. As one of the leading causes of acute gastroenteritis worldwide, NoV is associated with a substantial healthcare burden.

Dec 23, 2024 · Most significant clinical trials of 2024. From GLP-1RA and HIV PrEP successes, to flops in DMD and Alzheimer’s, Clinical Trials Arena rounds up the biggest trial read outs of 2024.

Sep 25, 2024 · GSK recently announced the discontinuation of its herpes simplex virus (HSV) therapeutic vaccine candidate, GSK3943104, following the failure of a Phase I/II clinical trial to meet its primary efficacy goals.. The vaccine aimed to reduce lesions in patients with recurrent genital herpes – a high unmet medical need. Although deemed safe, its lack of efficacy led to GSK’s decision not to ...

Oct 1, 2024 · Cobenfy is also being developed as an adjunctive therapy in patients who have an inadequate response to atypical antipsychotic monotherapy. The ongoing Phase III ARISE trial is a six-week, randomised, double-blind, placebo-controlled, multicentre, outpatient study in patients with schizophrenia with an inadequate response to their current atypical antipsychotic treatment.

Sep 13, 2024 · The vaccine was safe and well tolerated in the first cohort, with adverse events (AEs) including fatigue, injection site pain and fever. Researchers are asking for the interim data to be treated with caution at this early stage due to the small sample size and primary endpoint being safety and dose-determining.

Nov 20, 2024 · MSD has reported positive topline outcomes from the Phase III MK-3475A-D77 study assessing the noninferiority of subcutaneous Keytruda (pembrolizumab) administration, in conjunction with chemotherapy, for the first-line treatment of individuals with metastatic non-small cell lung cancer (NSCLC).. Pembrolizumab is available for intravenous use as Keytruda.

Dec 30, 2024 · The trial is designed to evaluate the therapy for treating hearing loss in infants and toddlers, aged six to 31 months. Credit: StoryTime Studio/Shutterstock. Sensorion has completed subject enrolment in the first cohort of Phase I/II Audiogene trial of gene therapy injection, SENS-501 for treating ...

Oct 23, 2024 · It aims to assess the efficacy and safety of sibeprenlimab 400mg administered every four weeks subcutaneously, in comparison to a placebo. An independent data monitoring committee conducted a pre-specified interim analysis, in which it concluded that sibeprenlimab led to a significant reduction in the 24-hour urine protein-to-creatine ratio (uPCR) after nine months of receiving the treatment.

Dec 18, 2023 · The year 2023 started with disappointing news for the field of human immunodeficiency virus (HIV) research after Janssen’s Phase III vaccine trial failed.. This setback has had a major impact on the industry and emphasised the need for better treatment and prevention against the virus while researchers continue to push for a vaccine.

Oct 16, 2024 · Between 2022 and 2023, the MHRA undertook a consultation period surrounding a new legislative framework for clinical trials in the UK. The MHRA said the new regulation will ensure patients and their safety are the focus of all clinical trials, while bringing the benefits of clinical trials to everyone.